Shots: The approval is based on trial results assessing Xolair IV (q2w or q4w) in 1M patients with SAA and CSU for 13 years The study demonstrated in reduction of severe exacerbations, corticosteroid […]readmore
Tags : (SAA)
Shots: The US FDA grants BT designation to Promacta (eltrombopag) + standard immunosuppressive therapy (SIT) for patients with 1L severe aplastic anemia (SAA) The BT designation is based on research […]readmore